_how-quantitative-measure-of-the-heart-sound-can-help-us-identify-abnormal-heart-conditions.jpg "How quantitative measure of the heart sound can help us identify abnormal heart conditions? from amita health patient login Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 18:20
👁 View: 10K times
✓ Published: 13-May-2024
👁 View: 10K times
✓ Published: 13-May-2024
Description:
This project focuses on analyzing the heart sound (auscultation) usually used by physicians to identify cases of abnormal heart condition. <br/><br/>The heart auscultation compared in this video focuses primarily on Patent ductus arteriosus (PDA) patients and compares them to a healthy person. <br/><br/>Spectrogram is a quantitative measure that representsthe spectrum of frequencies of a signal as it varies with time. The spectrogram of a PDA patient is compared to a healthy individual for quantitative preliminary diagnostic purposes, <br/><br/>#audioprocessing #digitalsignalprocessing #algorithm #matlab #engineeringprojects #signalprocessing
This project focuses on analyzing the heart sound (auscultation) usually used by physicians to identify cases of abnormal heart condition. <br/><br/>The heart auscultation compared in this video focuses primarily on Patent ductus arteriosus (PDA) patients and compares them to a healthy person. <br/><br/>Spectrogram is a quantitative measure that representsthe spectrum of frequencies of a signal as it varies with time. The spectrogram of a PDA patient is compared to a healthy individual for quantitative preliminary diagnostic purposes, <br/><br/>#audioprocessing #digitalsignalprocessing #algorithm #matlab #engineeringprojects #signalprocessing
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_patient-portal-key-features.webp "FollowMyHealth")
_prognocis-patient-portal-portal-login-amp-dashboard.webp "Bizmatics Inc")
_new-hope-for-patients-with-treatment-resistant-depression.webp "1 in 5 people could be diagnosed with depression or another serious mental illness in their lives. For some, a drug which can cause a loss of feeling or awareness is showing promising signs against treatment-resistant depression. If this story has raised issues for you, you can call Lifeline on 13 11 14")
_patient-portal-sign-up-instructions.webp "Bantoo Sehgal, M.D.")
_review-launched-into-suicides-at-brisbane-mental-health-unit.webp "Three people have died by suicide inside a locked mental health unit at a major Brisbane public hospital over the past 16 months.")
_124-nutritionistamita-124-summer-diet-marathi-podcast-amuktamuk.webp "Amuk Tamuk")
⏲ 1 hour 1 minute 38 seconds 👁 88.6K
_qampa-civil-marriage-soul-amp-day-trading-harav-yitzchak-breitowitz.webp "Ohr Somayach")
⏲ 1 hour 46 minutes 16 seconds 👁 2K
_new-analysis-suggests-long-term-effectiveness-for-wegovy-users.webp "New Analysis Suggests , Long-Term Effectiveness , for Wegovy Users .<br/>NBC reports that patients taking <br/>Novo Nordisk's obesity treatment maintain <br/>an average of 10% weight loss over four years.<br/>The news potentially boosts the <br/>drugmaker's push for Wegovy to be <br/>covered by insurers and governments. .<br/>The company submitted long-term <br/>findings at the European Congress <br/>on Obesity in Venice, Italy. .<br/>This is the longest study <br/>we’ve conducted so far of <br/>semaglutide for weight loss, Martin Holst Lange, Novo’s head of development, via NBC.<br/>We see that once the majority <br/>of the weight loss is accrued, <br/>you don’t go back and start <br/>to increase in weight<br/>if you stay on the drug, Martin Holst Lange, Novo’s head of development, via NBC.<br/>According to another analysis published by <br/>the drugmaker, approximately 17% of trial participants stopped using the treatment <br/>due to side effects like nausea. .<br/>The costly treatment ranges from $200 <br/>to nearly $2,000 per month in the ten <br/>countries where the drug is available.<br/>NBC reports that Novo Nordisk was the <br/>first drugmaker to market GLP-1 agonists, <br/>originally developed as a diabetes treatment, <br/>to address record high obesity rates.<br/>NBC reports that Novo Nordisk was the <br/>first drugmaker to market GLP-1 agonists, <br/>originally developed as a diabetes treatment, <br/>to address record high obesity rates.<br/>Rival Eli Lilly launched its drug <br/>Zepbound in the United States <br/>in December of 2023. .<br/>Neither drugmaker has managed <br/>to produce enough of the <br/>treatment to meet surging demand")
_patient-portal-key-features.jpg)
_prognocis-patient-portal-portal-login-amp-dashboard.jpg)
_new-hope-for-patients-with-treatment-resistant-depression.jpg)
_patient-portal-sign-up-instructions.jpg)
_review-launched-into-suicides-at-brisbane-mental-health-unit.jpg)
_124-nutritionistamita-124-summer-diet-marathi-podcast-amuktamuk.jpg)
_qampa-civil-marriage-soul-amp-day-trading-harav-yitzchak-breitowitz.jpg)
_new-analysis-suggests-long-term-effectiveness-for-wegovy-users.jpg)
![[+]](/images/menu.gif){kind=small}